Survodutide Peptide | Survodutide

Survodutide is a synthetic dual agonist peptide that stimulates two different receptors involved in metabolic control. Its research code is BI 456906.

Boehringer Ingelheim is working with Zealand Pharma to develop survodutide. Survodutide is made to take advantage of the complimentary effects of both GLP-1 and glucagon agonism, in contrast to conventional GLP-1 receptor agonists that only affect one route.

It is presently being assessed in a sizable Phase 3 clinical trial program called SYNCHRONISE, mainly for individuals with obesity and metabolic dysfunction-associated steatohepatitis (MASH), a dangerous liver disease closely connected with insulin resistance and obesity.

Survodutide Peptide

The effects of survodutide are produced by two different processes that operate simultaneously.
Activation of the GLP-1 Receptor (Appetite Control)

Similar to well-known GLP-1 medications, Survodutide Peptide increases feelings of fullness (satiety) after eating, suppresses appetite, and slows stomach emptying by activating GLP-1 receptors in the brain. This lowers caloric intake, which is the main cause of weight reduction.
Activation of the Glucagon Receptor (Direct Effects on the Liver and Metabolism)

The primary characteristic that sets Survodutide Peptidee apart is its glucagon receptor action. The hormone glucagon directly affects the liver to control the generation of glucose and the metabolism of fat. Through glucagon receptor activation, Survodutide Peptide may:

Encourage hepatic lipid oxidation to lower the amount of fat in the liver.

Reduce liver inflammation to enhance metabolic performance

Increase energy expenditure beyond what GLP-1 agonism can accomplish on its own

Patients with advanced liver disease may benefit from improved fibrosis.

According to preclinical study published in 2026, survodutide activates brain areas linked to appetite regulation, and its superior weight-lowering and metabolic effects in animal models depend on hepatic GCGR activity.

Unlike the GLP-1/GIP dual agonist tirzepatide, survodutide is a member of a more recent class of medications called dual incretin-based agonists since it activates two different pathways.